Immunic (NASDAQ:IMUX) shares saw an uptick in trading volume on Thursday . 3,597,794 shares traded hands during mid-day trading, an increase of 1,873% from the previous session’s volume of 182,375 shares.The stock last traded at $14.05 and had previously closed at $10.94.
Separately, Chardan Capital began coverage on Immunic in a research report on Thursday. They issued a “buy” rating and a $40.00 target price for the company.
Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Wednesday, April 10th. The company reported ($8.80) EPS for the quarter.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
Further Reading: Outstanding Shares
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.